The promising preliminary survival and remission outcomes that inotuzumab ozogamicin produced in relapsed or refractory acute lymphoblastic leukemia patients in the antibody-drug conjugate’s Phase 3 trial have been sustained in a long-term follow-up study.
Remission rates of elderly ALL patients on a novel, lower-toxicity immunotherapy regimen appear to at least equal those observed with conventional chemotherapy.
Patients with relapsed/refractory ALL who were treated in a clinical trial with the antibody-drug conjugate inotuzumab ozogamicin experienced much higher remission rates compared with the standard of care, a new study reports.
AML studies report effectiveness of vadastuximab, an anti-CD33 drug conjugate, in various regimens including combined with azacitidine and as part of maintenance regimens. Investigators predict changes to standard treatment of AML in the near future.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The prognosis for ALL is poor and therapy has not changed for a decade. The drug inotuzumab ozogamicin now holds promise to change that outlook and improve outcomes.
Several promising antibody-based treatment strategies are in development for acute lymphoblastic leukemia and acute myeloid leukemia. These could change the decade-old treatment paradigm.
Early study results show significant improvement for young adult acute lymphoblastic leukemia patients on pediatric treatment regimen as compared to conventional adult regimens.
Seattle Genetics has developed a novel antibody-drug conjugate that shows promise in treating patients with CD33-positive acute myeloid leukemia. SGN-CD33A targets cells expressing CD33.